Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B-Lymphocyte Subsets | 14 | 2020 | 18 | 4.910 |
Why?
|
| B-Lymphocytes | 24 | 2019 | 69 | 4.250 |
Why?
|
| Immunoglobulin M | 10 | 2020 | 16 | 2.680 |
Why?
|
| T-Lymphocytes | 5 | 2020 | 114 | 2.430 |
Why?
|
| Mice, Inbred C57BL | 22 | 2020 | 711 | 2.250 |
Why?
|
| Antibody Formation | 9 | 2019 | 39 | 2.110 |
Why?
|
| Mice | 42 | 2020 | 2368 | 1.970 |
Why?
|
| Peritoneal Neoplasms | 3 | 2020 | 241 | 1.710 |
Why?
|
| Cord Factors | 3 | 2020 | 3 | 1.670 |
Why?
|
| Lipid A | 3 | 2020 | 4 | 1.670 |
Why?
|
| Lymphocyte Activation | 11 | 2020 | 80 | 1.580 |
Why?
|
| Animals | 48 | 2020 | 7297 | 1.410 |
Why?
|
| Streptococcus pneumoniae | 5 | 2019 | 40 | 1.410 |
Why?
|
| Receptors, Complement 3d | 9 | 2009 | 11 | 1.380 |
Why?
|
| Immunoglobulin G | 11 | 2020 | 104 | 1.360 |
Why?
|
| Adjuvants, Immunologic | 8 | 2020 | 51 | 1.360 |
Why?
|
| Immunity, Innate | 5 | 2018 | 64 | 1.350 |
Why?
|
| Antigens, CD19 | 8 | 2018 | 9 | 1.350 |
Why?
|
| Antigens, T-Independent | 3 | 2020 | 3 | 1.260 |
Why?
|
| Mice, Knockout | 16 | 2020 | 425 | 1.210 |
Why?
|
| Receptors, Complement 3b | 5 | 2009 | 7 | 1.170 |
Why?
|
| Pneumococcal Infections | 4 | 2019 | 30 | 1.160 |
Why?
|
| Pneumococcal Vaccines | 3 | 2019 | 25 | 1.140 |
Why?
|
| Antibodies, Bacterial | 5 | 2019 | 31 | 1.130 |
Why?
|
| Lectins, C-Type | 3 | 2020 | 10 | 1.090 |
Why?
|
| Toll-Like Receptors | 3 | 2020 | 22 | 1.080 |
Why?
|
| Signal Transduction | 14 | 2020 | 666 | 1.040 |
Why?
|
| Immunologic Memory | 3 | 2020 | 31 | 0.940 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2020 | 12 | 0.930 |
Why?
|
| Cell Differentiation | 7 | 2020 | 436 | 0.870 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2020 | 41 | 0.860 |
Why?
|
| Peritoneal Cavity | 3 | 2018 | 5 | 0.760 |
Why?
|
| Antigens, Ly | 1 | 2020 | 6 | 0.750 |
Why?
|
| Interferon Type I | 1 | 2020 | 14 | 0.740 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 2016 | 3 | 0.740 |
Why?
|
| Polysaccharides, Bacterial | 5 | 2015 | 10 | 0.740 |
Why?
|
| Polysaccharides | 1 | 2019 | 13 | 0.690 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 10 | 0.670 |
Why?
|
| Cells, Cultured | 13 | 2019 | 799 | 0.670 |
Why?
|
| Receptors, Antigen, B-Cell | 8 | 2018 | 11 | 0.640 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 5 | 0.620 |
Why?
|
| Autoantibodies | 3 | 2014 | 41 | 0.620 |
Why?
|
| Gene Expression Regulation | 5 | 2015 | 481 | 0.530 |
Why?
|
| Complement C4 | 1 | 2014 | 4 | 0.510 |
Why?
|
| Primates | 1 | 2015 | 100 | 0.510 |
Why?
|
| Streptococcal Infections | 1 | 2014 | 20 | 0.510 |
Why?
|
| Antigens | 2 | 2013 | 31 | 0.470 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2013 | 12 | 0.470 |
Why?
|
| Epitopes | 1 | 2013 | 21 | 0.460 |
Why?
|
| Cell Proliferation | 5 | 2020 | 573 | 0.460 |
Why?
|
| Antigens, CD20 | 6 | 2010 | 7 | 0.450 |
Why?
|
| Neoplasms | 3 | 2016 | 610 | 0.440 |
Why?
|
| Down-Regulation | 2 | 2019 | 143 | 0.440 |
Why?
|
| Growth Inhibitors | 2 | 2011 | 7 | 0.430 |
Why?
|
| Macrophages | 4 | 2020 | 188 | 0.410 |
Why?
|
| Antigens, Surface | 2 | 2015 | 19 | 0.390 |
Why?
|
| Immunity, Humoral | 5 | 2015 | 12 | 0.370 |
Why?
|
| Cattle | 6 | 2003 | 100 | 0.370 |
Why?
|
| Lupus Nephritis | 1 | 2010 | 30 | 0.360 |
Why?
|
| Immunization | 4 | 2016 | 28 | 0.360 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 16 | 0.360 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 33 | 0.350 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2010 | 145 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 6 | 2010 | 196 | 0.340 |
Why?
|
| Autoimmunity | 2 | 2005 | 26 | 0.320 |
Why?
|
| Complement C3d | 2 | 2005 | 2 | 0.320 |
Why?
|
| Lymphocyte Depletion | 6 | 2010 | 14 | 0.310 |
Why?
|
| Female | 10 | 2020 | 18164 | 0.300 |
Why?
|
| Leukemia, B-Cell | 1 | 2006 | 4 | 0.290 |
Why?
|
| Male | 8 | 2019 | 17807 | 0.260 |
Why?
|
| Phagocytes | 2 | 2020 | 5 | 0.250 |
Why?
|
| Mice, Transgenic | 4 | 2016 | 249 | 0.250 |
Why?
|
| Homeostasis | 2 | 2017 | 127 | 0.240 |
Why?
|
| Immunotherapy | 5 | 2008 | 69 | 0.240 |
Why?
|
| Bacterial Vaccines | 2 | 2019 | 7 | 0.230 |
Why?
|
| Cell Division | 3 | 2020 | 97 | 0.230 |
Why?
|
| Antibodies | 2 | 2008 | 53 | 0.220 |
Why?
|
| Macaca fascicularis | 2 | 2015 | 389 | 0.220 |
Why?
|
| Ficoll | 2 | 2013 | 2 | 0.220 |
Why?
|
| Trinitrobenzenes | 2 | 2013 | 2 | 0.220 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 980 | 0.210 |
Why?
|
| Lymphoma, B-Cell | 3 | 2012 | 12 | 0.210 |
Why?
|
| Trypanosoma congolense | 1 | 2001 | 1 | 0.210 |
Why?
|
| Trypanosomiasis, African | 1 | 2001 | 7 | 0.210 |
Why?
|
| Ligands | 5 | 2007 | 81 | 0.200 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 4 | 0.190 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 2 | 0.190 |
Why?
|
| Immunoglobulin A | 2 | 2014 | 9 | 0.190 |
Why?
|
| Carrier Proteins | 1 | 2001 | 131 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 158 | 0.180 |
Why?
|
| Lymphoma | 1 | 2020 | 36 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 113 | 0.180 |
Why?
|
| Antigens, Nuclear | 1 | 2019 | 6 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2001 | 256 | 0.180 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 15 | 0.170 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2019 | 7 | 0.170 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 273 | 0.170 |
Why?
|
| Antibody-Producing Cells | 1 | 2019 | 3 | 0.170 |
Why?
|
| Apoptosis | 2 | 2020 | 337 | 0.170 |
Why?
|
| Disease Susceptibility | 2 | 2013 | 53 | 0.170 |
Why?
|
| Vaccines, Conjugate | 1 | 2019 | 15 | 0.170 |
Why?
|
| DNA Repair | 1 | 2019 | 50 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2012 | 28 | 0.170 |
Why?
|
| Mice, Inbred A | 1 | 2018 | 4 | 0.170 |
Why?
|
| Protein Binding | 4 | 2019 | 199 | 0.170 |
Why?
|
| Humans | 13 | 2020 | 29093 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 249 | 0.170 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 3 | 0.160 |
Why?
|
| Interleukin-5 | 1 | 2017 | 7 | 0.160 |
Why?
|
| Syndecan-1 | 1 | 2017 | 7 | 0.160 |
Why?
|
| Vaccination | 1 | 2019 | 123 | 0.160 |
Why?
|
| Complement System Proteins | 2 | 2009 | 9 | 0.150 |
Why?
|
| Receptors, IgE | 2 | 2007 | 2 | 0.150 |
Why?
|
| Mucins | 1 | 2016 | 18 | 0.150 |
Why?
|
| Immunoglobulin E | 2 | 2007 | 47 | 0.150 |
Why?
|
| Receptors, IgG | 2 | 2008 | 7 | 0.150 |
Why?
|
| Spleen | 3 | 2013 | 82 | 0.140 |
Why?
|
| Carbohydrates | 1 | 2016 | 6 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2015 | 440 | 0.140 |
Why?
|
| Cell Survival | 3 | 2006 | 272 | 0.140 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 3 | 2005 | 5 | 0.140 |
Why?
|
| Lectins | 3 | 2005 | 10 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 21 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2017 | 172 | 0.140 |
Why?
|
| Cell Adhesion Molecules | 3 | 2005 | 45 | 0.140 |
Why?
|
| src-Family Kinases | 3 | 2005 | 16 | 0.140 |
Why?
|
| Antigens, CD | 3 | 2005 | 100 | 0.140 |
Why?
|
| Cytokines | 3 | 2008 | 243 | 0.130 |
Why?
|
| Species Specificity | 1 | 2015 | 84 | 0.130 |
Why?
|
| Phenotype | 4 | 2015 | 629 | 0.130 |
Why?
|
| Cross Reactions | 1 | 2014 | 5 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2014 | 5 | 0.130 |
Why?
|
| Phosphatidylcholines | 1 | 2014 | 21 | 0.130 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2014 | 13 | 0.130 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 680 | 0.120 |
Why?
|
| Calcium | 3 | 2006 | 296 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 666 | 0.120 |
Why?
|
| DNA | 1 | 2014 | 204 | 0.110 |
Why?
|
| Diet | 1 | 2015 | 354 | 0.110 |
Why?
|
| Haptens | 1 | 2011 | 1 | 0.100 |
Why?
|
| Splenectomy | 1 | 2011 | 19 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 158 | 0.100 |
Why?
|
| Cysteine | 1 | 2012 | 131 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 836 | 0.100 |
Why?
|
| Immunophenotyping | 4 | 2008 | 49 | 0.100 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2010 | 1 | 0.100 |
Why?
|
| B-Cell Activating Factor | 1 | 2010 | 2 | 0.100 |
Why?
|
| Kidney | 1 | 2014 | 485 | 0.090 |
Why?
|
| Mice, Inbred NZB | 1 | 2010 | 4 | 0.090 |
Why?
|
| Lymphoid Tissue | 2 | 2007 | 10 | 0.090 |
Why?
|
| Terpenes | 1 | 2010 | 4 | 0.090 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 23 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 23 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 1108 | 0.090 |
Why?
|
| Receptors, Fc | 2 | 2006 | 6 | 0.090 |
Why?
|
| Antigens, Bacterial | 1 | 2009 | 18 | 0.090 |
Why?
|
| Inflammation | 2 | 2015 | 507 | 0.090 |
Why?
|
| CD40 Ligand | 3 | 2011 | 13 | 0.090 |
Why?
|
| Time Factors | 2 | 2011 | 2001 | 0.080 |
Why?
|
| Models, Biological | 3 | 2007 | 373 | 0.080 |
Why?
|
| Interleukin-10 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Plasma Cells | 1 | 2008 | 8 | 0.080 |
Why?
|
| Prions | 1 | 2007 | 3 | 0.080 |
Why?
|
| Survival Rate | 1 | 2010 | 795 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1063 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2007 | 70 | 0.080 |
Why?
|
| Nippostrongylus | 1 | 2007 | 1 | 0.080 |
Why?
|
| Strongylida Infections | 1 | 2007 | 2 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 36 | 0.070 |
Why?
|
| Norepinephrine | 1 | 2006 | 73 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2002 | 20 | 0.070 |
Why?
|
| Immune System | 1 | 2005 | 8 | 0.070 |
Why?
|
| Feedback, Physiological | 1 | 2005 | 10 | 0.070 |
Why?
|
| Scleroderma, Systemic | 1 | 2005 | 7 | 0.070 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2004 | 2 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2003 | 514 | 0.060 |
Why?
|
| Bacteria | 1 | 2005 | 45 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2004 | 2 | 0.060 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2004 | 5 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2004 | 3 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2005 | 67 | 0.060 |
Why?
|
| Streptavidin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Immunization, Secondary | 1 | 2004 | 9 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2004 | 5 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 73 | 0.060 |
Why?
|
| Cullin Proteins | 1 | 2004 | 4 | 0.060 |
Why?
|
| HIV-1 | 1 | 2004 | 42 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 32 | 0.060 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2004 | 44 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 48 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2003 | 7 | 0.060 |
Why?
|
| Cell Line | 2 | 2004 | 449 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 71 | 0.060 |
Why?
|
| Receptors, Mitogen | 1 | 2002 | 2 | 0.060 |
Why?
|
| Parasitic Diseases | 1 | 2002 | 5 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2002 | 11 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2002 | 10 | 0.060 |
Why?
|
| Immunity | 1 | 2002 | 19 | 0.060 |
Why?
|
| Mutation | 1 | 2005 | 466 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 58 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2003 | 61 | 0.050 |
Why?
|
| Proteins | 1 | 2003 | 140 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2001 | 71 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2001 | 4 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 11 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2001 | 40 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 97 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2000 | 7 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 97 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2012 | 225 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 165 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 572 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 248 | 0.040 |
Why?
|
| Autoimmune Diseases | 2 | 2008 | 50 | 0.040 |
Why?
|
| Cell Membrane | 2 | 2007 | 97 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 126 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 22 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 32 | 0.030 |
Why?
|
| Calcium Signaling | 2 | 2005 | 40 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 540 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2012 | 8 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2012 | 8 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 20 | 0.030 |
Why?
|
| Cyclohexanones | 1 | 2012 | 17 | 0.030 |
Why?
|
| Biological Transport | 1 | 2012 | 62 | 0.030 |
Why?
|
| Actins | 1 | 2012 | 52 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2015 | 327 | 0.030 |
Why?
|
| Cell Count | 1 | 2011 | 50 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2010 | 171 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 281 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2008 | 1 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 51 | 0.020 |
Why?
|
| Integrin alpha4beta1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 43 | 0.020 |
Why?
|
| Prion Diseases | 1 | 2007 | 3 | 0.020 |
Why?
|
| Antigens, Helminth | 1 | 2007 | 1 | 0.020 |
Why?
|
| Alum Compounds | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 23 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 114 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Silver | 1 | 2007 | 8 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 160 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2006 | 13 | 0.020 |
Why?
|
| Solubility | 1 | 2006 | 38 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2005 | 14 | 0.020 |
Why?
|
| Complement C3 | 1 | 2005 | 7 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2005 | 10 | 0.020 |
Why?
|
| Kinetics | 1 | 2005 | 205 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 50 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 31 | 0.020 |
Why?
|
| Hybridomas | 1 | 2004 | 2 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 82 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 69 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 9 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 33 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 28 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 36 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 161 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2003 | 7 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 90 | 0.010 |
Why?
|
| Leukocytes | 1 | 2003 | 52 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 77 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 66 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 9 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 64 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 240 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 280 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2002 | 9 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 350 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2002 | 15 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2003 | 74 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 248 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 136 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 3099 | 0.010 |
Why?
|